ExpreS2ion announces poster presentation on ES2B-C001 at the AACR Annual Meeting 2023
Hørsholm, Denmark, 18 April 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announces that the company through its research collaboration partners at University of Bologna presented a poster on ES2B-C001, our unique HER2-VLP breast cancer vaccine candidate, at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
The presentation poster titled “Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis” concludes, that:
- ES2B-C001 vaccination inhibited the onset, growth, and metastatic spread of HER-2 positive mammary carcinomas in mice.
- The vaccine induced strong and persistent antibody responses that inhibited human HER-2+ breast and gastric cancer cells in vitro.
- ES2B-C001 is a promising candidate vaccine for the therapy of human tumours expressing HER-2. Preclinical results warrant further development towards human clinical studies.
A copy of the poster can be found at the company webpage at https://expres2ionbio.com/meet-us/
Certified Adviser
Svensk Kapitalmarknadsgranskning AB